Interim results report 94% efficacy with Moderna/NIH mRNA vaccine: FDA hearing on 17 December

Simon Collins, HIV i-Base

On 16 November 2020, a press statement from the UK NIH (a partner with Moderna for the mRNA-1273 vaccine) announced 94% efficacy in an interim analysis from the ongoing phase 3 COVE study. [1]

The results, released from the trial’s Data and Safety Monitoring Board (DSMB) reported 95 cases of symptomatic infection: 90 vs 5 cases in the placebo vs vaccine groups, respectively.

Additionally, all 11/95 cases of severe COVID-19 were in placebo recipients.

The study was launched on 27 July 2020 and has enrolled 30,000 participants at 100 sites in the US. [2]

The FDA advisory committee hearing for this vaccine is due on 17 December 2020. Meeting amterials are posted online and the hearing is webcast. [3]


  1. NIH press statement. Promising interim results from clinical trial of NIH-Moderna COVID-19 Vaccine/ (16 November 2020).
  2. A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19.
  3. Vaccines and related biological products advisory committee: December 17, 2020 meeting announcement.

Links to other websites are current at date of posting but not maintained.